According to an analysis by Dr. Laxmaiah Manchikanti, approximately 9 million ESIs are performed annually.
The corticosteroids utilized in these injections are not specifically FDA-approved for this particular use.
Advanced Injury & DISC Center
Advanced Injury & DISC Center
Advanced Injury & DISC Center
FDA Issues Warning Regarding Epidural Steroid Injections
for Back Pain
The U.S. Food and Drug Administration (FDA) has issued
a MedWatch Alert regarding epidural steroid injections (ESIs) for back and neck pain.
The alert states that "Injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events,
including loss of vision, stroke, paralysis, and death".
ESIs involve injecting corticosteroids into the epidural space, an area located between the spinal cord and the bony structure of the spine.
01
Unapproved Use and Frequency of Injections
02
Labeling Changes and Identified Risks
The FDA is now mandating the addition of a Warning to the drug labels of injectable corticosteroids, including methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone, to describe these risks.
While this new warning aims to highlight the risks associated with injecting steroids into the epidural space, it does not enumerate all possible adverse reactions.
These reactions, detailed in the fine print of current drug labels, include:
"arachnoiditis, bowel/bladder dysfunction, headache, meningitis, parapareisis/paraplegia, seizures, sensory disturbances".
03
Ongoing FDA Review and Advocacy Efforts
In contrast to the FDA's current stance, health authorities in Australia and New Zealand issued a stronger statement, asserting that steroids "MUST NOT be used by the intrathecal, epidural, intravenous or any other unspecified routes".
Dennis Capolongo of the Epidural Drug Non-Compliance (EDNC) group, which advocates against ESIs, characterized the FDA's new warning as "bitter sweet," suggesting it did not go far enough. Capolongo advocates for the FDA to issue a stronger directive, prohibiting the use of these steroids in the epidural space, rather than merely stating that severe side effects "could" occur.
04
International Regulatory Actions
In contrast to the FDA's current stance, health authorities in Australia and New Zealand issued a stronger statement, asserting that steroids "MUST NOT be used by the intrathecal, epidural, intravenous or any other unspecified routes".
The South African government has reportedly issued similar warnings.
The FDA's continued study of these procedures suggests that further actions from the agency may be forthcoming.
